Abstract: Compositions of exosomes are provided that include a plurality of exosomes and a biocompatible cryoprotectant, such that the exosomes are suspended in the biocompatible cryoprotectant as a colloidal suspension of exosomes. Preferably, the cryoprotectant is a carboxylated E-poly-l-lysine (COOH-PLL) cryoprotectant, but other moieties might be extended to the claim of hybridization polymers to incorporate preferred embodiments for lineage and tissue specific intentions. The colloidal suspension of exosomes can be frozen at ?65 degrees C. or colder and thereafter stored as a frozen composition of exosomes or can be freeze-dried and thereafter stored at ambient conditions in a vacuum sealed container. Also provided are kits comprising the composition of exosomes and methods of making the compositions of exosomes.

Abstract: A biological composition intermixed with a polyampholyte protectant for direct implantation has a mixture of biologic material and a volume of polyampholyte protectant. The mixture of biologic material has non-whole cellular components including vesicular components and active and inactive components of biological activity, cell fragments, cellular excretions, cellular derivatives, and extracellular components, or whole cells or combinations of the non-whole cellular components and whole cells, wherein the mixture is compatible with biologic function. The volume of polyampholyte protectant is intermixed with the mixture of biologic material, wherein the polyampholyte protectant is a liquid of a polyamine polymer compound of carboxylated poly-lysine and wherein the polyampholyte protectant forms a three-dimensional bonding shroud externally enveloping each of the non-whole cellular components, if any, and each of the whole cells, if any, of the mixture of biologic material.

Abstract: Compositions of exosomes are provided that include a plurality of exosomes and a biocompatible cryoprotectant, such that the exosomes are suspended in the biocompatible cryoprotectant as a colloidal suspension of exosomes. Preferably, the cryoprotectant is a carboxylated E-poly-1-lysine (COOH-PLL) cryoprotectant, but other moieties might be extended to the claim of hybridization polymers to incorporate preferred embodiments for lineage and tissue specific intentions. The colloidal suspension of exosomes can be frozen at ?65 degrees C. or colder and thereafter stored as a frozen composition of exosomes or can be freeze-dried and thereafter stored at ambient conditions in a vacuum sealed container. Also provided are kits comprising the composition of exosomes and methods of making the compositions of exosomes.

Abstract: The present invention comprises poly(vinyl benzoate) nanoparticle suspensions as molecular carriers. These nanoparticles can be formed by nanoprecipitation of poly(vinyl benzoate) in water using Pluronic F68 as surfactant, to create spherical nanostructures measuring about 200-250 nm in diameter which are stable in phosphate buffer and blood serum, and only slowly degrade in the presence of esterases. Kinetics experiments in phosphate buffer indicate that 78% of the coumarin-6 was encapsulated within the polymer matrix of the nanoparticle, and the residual 22% of coumarin-6 was surface-bound and quickly released. The nanoparticles are non-toxic in vitro towards human epithelial cells (IC50>1000 ?g/mL) and primary bovine primary aortic endothelial cells (IC50>500 ?g/mL), and exert non-observable bactericidal activity against a selection of representative test microbes (MIC>250 ?g/mL).

Abstract: A biological composition intermixed with a polyampholyte protectant for direct implantation has a mixture of biologic material and a volume of polyampholyte protectant. The mixture of biologic material has non-whole cellular components including vesicular components and active and inactive components of biological activity, cell fragments, cellular excretions, cellular derivatives, and extracellular components, or whole cells or combinations of the non-whole cellular components and whole cells, wherein the mixture is compatible with biologic function. The volume of polyampholyte protectant is intermixed with the mixture of biologic material, wherein the polyampholyte protectant is a liquid of a polyamine polymer compound of carboxylated poly-lysine and wherein the polyampholyte protectant forms a three-dimensional bonding shroud externally enveloping each of the non-whole cellular components, if any, and each of the whole cells, if any, of the mixture of biologic material.

Abstract: The present invention comprises poly(vinyl benzoate) nanoparticle suspensions as molecular carriers. These nanoparticles can be formed by nanoprecipitation of poly(vinyl benzoate) in water using Pluronic F68 as surfactant, to create spherical nanostructures measuring about 200-250 nm in diameter which are stable in phosphate buffer and blood serum, and only slowly degrade in the presence of esterases. Kinetics experiments in phosphate buffer indicate that 78% of the coumarin-6 was encapsulated within the polymer matrix of the nanoparticle, and the residual 22% of coumarin-6 was surface-bound and quickly released. The nanoparticles are non-toxic in vitro towards human epithelial cells (IC50>1000 ?g/mL) and primary bovine primary aortic endothelial cells (IC50>500 ?g/mL), and exert non-observable bactericidal activity against a selection of representative test microbes (MIC>250 ?g/mL).

Abstract: The present invention comprises poly(vinyl benzoate) nanoparticle suspensions as molecular carriers. These nanoparticles can be formed by nanoprecipitation of poly(vinyl benzoate) in water using Pluronic F68 as surfactant, to create spherical nanostructures measuring about 200-250 nm in diameter which are stable in phosphate buffer and blood serum, and only slowly degrade in the presence of esterases. Kinetics experiments in phosphate buffer indicate that 78% of the coumarin-6 was encapsulated within the polymer matrix of the nanoparticle, and the residual 22% of coumarin-6 was surface-bound and quickly released. The nanoparticles are non-toxic in vitro towards human epithelial cells (IC50>1000 ?g/mL) and primary bovine primary aortic endothelial cells (IC50>500 ?g/mL), and exert non-observable bactericidal activity against a selection of representative test microbes (MIC>250 ?g/mL).

Abstract: The present invention comprises poly(vinyl benzoate) nanoparticle suspensions as molecular carriers. These nanoparticles can be formed by nanoprecipitation of poly(vinyl benzoate) in water using Pluronic F68 as surfactant, to create spherical nanostructures measuring about 200-250 nm in diameter which are stable in phosphate buffer and blood serum, and only slowly degrade in the presence of esterases. Kinetics experiments in phosphate buffer indicate that 78% of the coumarin-6 was encapsulated within the polymer matrix of the nanoparticle, and the residual 22% of coumarin-6 was surface-bound and quickly released. The nanoparticles are non-toxic in vitro towards human epithelial cells (IC50>1000 ?g/mL) and primary bovine primary aortic endothelial cells (IC50>500 ?g/mL), and exert non-observable bactericidal activity against a selection of representative test microbes (MIC >250 ?g/mL).